Search

IBM, WellPoint, Inc., and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.

… Friday, February 8, 2013 IBM (NYSE: IBM ), WellPoint, Inc. (NYSE: WLP ), and Memorial Sloan Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

… Tuesday, December 5, 2017 This past year, Memorial Sloan Kettering researchers made important advances in basic and translational science that furthered our understanding of cancer and of how best to treat it. Here, we describe some of the year’s highlights. First CAR T Cell Therapies FDA Approved By

Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK's drug development resources and a pathway for future collaboration via the Accelerator.

… Wednesday, April 30, 2025 MSK recently announced the launch of a new cohort program in the MSK Therapeutics Accelerator . Scheduled to start in Summer 2025, this cohort program will facilitate tailored mentorship with MSK faculty, while providing insight into MSK’s drug development resources and a pathway

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.

… Friday, February 5, 2021 Summary Research shows how a protein called MYB can be targeted, suggesting a new approach for drugs that could treat a range of cancers, especially myeloid leukemias in both children and adults. Disruption in the way genes turn on and off can cause tumors to grow and proliferate

New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different mutational processes impact individual cell genomes in cancer; sheds new light on cell senescence in cancer; and offers new models to aid the search for new treatments for mesothelioma.

… Wednesday, November 23, 2022 New research from Memorial Sloan Kettering Cancer Center (MSK) and the Sloan Kettering Institute — MSK’s experimental research arm — finds tumor-associated macrophages that express a specific transcription factor might be targeted to improve immunotherapy; examines how different

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.

… Thursday, August 10, 2023 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:  MSK Named Finalist for the 2023 U.S. Legal Department of the Year MSK’s Legal team has been recognized as of one of five finalists for the 2023 U.S. Legal Department of the Year

MSK researchers are learning how cells are able to recognize and correct errors that occur during cell division.

… Tuesday, May 9, 2017 Summary MSK researchers have uncovered new details about how a dividing cell is able to recognize and correct mistakes that occur during mitosis, one of the most important events in cell division. Highlights Studying the mechanisms of cell division gives researchers key insights

Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time - known as PSA velocity - is a poor predictor of prostate cancer and may lead to many unnecessary biopsies.

… Thursday, February 24, 2011 Screening for PSA Velocity Leads to Many Unnecessary Biopsies and Should Be Removed from Screening Guidelines Researchers at Memorial Sloan Kettering Cancer Center have found that change in PSA levels over time — known as PSA velocity — is a poor predictor of prostate cancer

Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, October 14, 2022 Carol Morris, MD, MS, has assumed the position of Chief of the Orthopaedic Surgery Service at Memorial Sloan Kettering Cancer Center (MSK). A skilled surgeon and talented leader, Dr. Morris has a deep familiarity with MSK, having previously spent 14 years at the institution as

Memorial Sloan Kettering researchers helped to identify a key insight into what first goes wrong in the development of many leukemias.

… Thursday, June 30, 2011 Researchers at Memorial Sloan Kettering Cancer Center and New York University have discovered how a mutation in the gene known as TET2 contributes to the development of some leukemias . When a mutation in TET2 occurs, it enhances the function of blood stem cells in the bone marrow